Melanoma metastasis is a devastating outcome lacking an effective preventative therapeutic. We provide pharmacologic, molecular, and genetic evidence establishing the liver-X nuclear hormone receptor (LXR) as a therapeutic target in melanoma. Oral administration of multiple LXR agonists suppressed melanoma invasion, angiogenesis, tumor progression, and metastasis. Molecular and genetic experiments revealed these effects to be mediated by LXRb, which elicits these outcomes through transcriptional induction of tumoral and stromal apolipoprotein-E (ApoE). LXRb agonism robustly suppressed tumor growth and metastasis across a diverse mutational spectrum of melanoma lines. LXRb targeting significantly prolonged animal survival, suppressed the progression of established metastases, and inhibited brain metastatic colonization. Importantly, LXRb activation displayed melanoma-suppressive cooperativity with the frontline regimens dacarbazine, B-Raf inhibition, and the anti-CTLA-4 antibody and robustly inhibited melanomas that had acquired resistance to B-Raf inhibition or dacarbazine. We present a promising therapeutic approach that uniquely acts by transcriptionally activating a metastasis suppressor gene.
INTRODUCTION
Metastasis, the dissemination of cancer cells from a primary tumor to distal organs, accounts for the majority of deaths incurred by solid tumors (Gupta and Massagué , 2006; Hanahan and Weinberg, 2011; Talmadge and Fidler, 2010) . The molecular and cell-biological complexity of metastatic progression, as well as its devastating toll on society, have triggered extensive investigations, leading to the identification of many coding and noncoding genes as regulators of the metastatic process (Kang et al., 2003; Minn et al., 2005; Ma et al., 2007; Tavazoie et al., 2008; Png et al., 2012; Pencheva et al., 2012) . In the past three decades, interdisciplinary preclinical and clinical efforts aimed at reducing metastatic relapse have lowered mortality rates and extended survival times for a number of cancer types. This is especially the case for hormonally driven malignancies, such as breast and prostate cancers, for which nuclear hormone receptor targeting of the estrogen or androgen receptors has proved to be an effective therapeutic approach (Deblois and Giguè re, 2013; Tran et al., 2009; Scher et al., 2012) .
Although nuclear hormone receptors have emerged as key therapeutic targets in breast and prostate malignancies, whose initiation and progression are intricately linked to the estrogen and testosterone sex hormones, the clinical potential of nuclear hormone receptor targeting in other solid cancers originating from nonreproductive tissues is unexplored. Melanoma, the most aggressive type of skin cancer with steeply increasing incidence, incurs $48,000 deaths annually worldwide (Lucas et al., 2006) . Presently, there are no effective therapies for the prevention of melanoma metastasis, with interferon-alpha, the only Food and Drug Administration (FDA)-approved melanoma adjuvant therapy, conferring a meager 5-year overall survival benefit of $1%-3% . The poor clinical prognosis and the lack of curative therapies for patients with advanced melanoma necessitate the development and implementation of novel approaches that prevent metastatic relapse of this cancer.
We herein demonstrate that targeting of a specific nuclear hormone receptor exhibits broad-spectrum efficacy in suppressing melanoma progression. We identify the nuclear hormone receptor LXRb as the major LXR isoform expressed by melanoma cells and show that pharmacologic modulation of LXRb strongly inhibits melanoma progression phenotypes of cell invasion, endothelial recruitment, tumor progression, and metastatic colonization. LXRb activation suppresses melanoma progression through the transcriptional induction of cancer-derived and stromal ApoE-a potent metastasis suppressor in melanoma (Pencheva et al., 2012) . Our findings from multiple mutationally diverse preclinical models of melanoma progression motivate the clinical testing of LXRb targeting for the treatment of metastatic melanoma.
RESULTS

Identification of LXRb Signaling as a Therapeutic Target in Melanoma
We had previously identified ApoE as a robust suppressor of melanoma metastasis (Pencheva et al., 2012) . We hypothesized that the transcriptional induction of ApoE might suppress melanoma progression. The impact of such ApoE activation might be heightened if an ApoE trans-activator would be expressed across melanoma and in normal tissues. Previously, analysis of nuclear hormone receptor expression in the NCI60 cell line collection had revealed several receptors to exhibit stable expression in melanoma (Holbeck et al., 2010) . Notably, of these nuclear receptors, the liver-X receptors (LXRs) had been previously found to enhance transcription of ApoE and other targets in adipocytes and macrophages (Laffitte et al., 2001) , whereas pharmacologic activation of retinoid X receptors (RXRs) had been shown to drive the expression of ApoE as well (Mak et al., 2002) . We further confirmed the expression of LXRs and RXRs in melanoma and detected expression of LXRb and RXRb in seven independently established primary melanoma lines obtained from multiple melanoma patients ( Figure 1A ). Given the ubiquitous basal expression of LXRb and RXRb in melanoma, the recently uncovered metastasis-suppressive role of ApoE (Pencheva et al., 2012) , and the availability of pharmacologic agents to therapeutically activate LXRs and RXRs, we investigated whether activation of LXRs or RXRs might inhibit melanoma progression phenotypes. We first examined whether pharmacologic agonism of LXRs or RXRs in melanoma cells affects in vitro cell growth. Treatment of melanoma cells with two structurally distinct LXR agonists, GW3965 or T0901317, or the RXR agonist bexarotene did not affect cell proliferation or viability rates (Figures S1A-S1F available online). We next assessed the effects of LXR or RXR activation on cell invasion and endothelial recruitment-phenotypes displayed by metastatic melanoma and metastatic breast cancer populations (Pencheva et al., 2012; Png et al., 2012) . Treatment of the mutationally diverse MeWo, HT-144, and SK-Mel-2 human melanoma lines as well as the SK-Mel-334.2 primary human melanoma line with LXR agonists consistently suppressed melanoma invasion through matrigel ( Figures 1B-1E ) and endothelial recruitment by melanoma cells in trans-well assays ( Figures 1F-1J ). In comparison, treatment with the RXR agonist bexarotene suppressed invasion in only half of the melanoma lines tested and did not significantly affect endothelial recruitment ( Figures 1B-1J ), suggesting that RXR activation might modulate an effector that antagonizes the effects of ApoE on these phenotypes. Given the superiority of LXR over RXR agonism, we investigated the requirement for LXR signaling in mediating the suppressive effects of LXR agonists by depleting each LXR isoform in melanoma cells. Knockdown of melanoma cell LXRb, but not LXRa, abrogated the ability of GW3965 and T0901317 to suppress invasion and endothelial recruitment ( Figures 1K-1N and S1G-S1J), revealing melanoma cell LXRb to be the effector of LXR agonists in suppressing these phenotypes. Importantly, LXRb was the predominant LXR isoform expressed by melanoma cells ( Figure 1A , p < 0.0001) and was also ubiquitously expressed across primary and metastatic human melanoma clinical samples ( Figures S1K and S1L ).
Therapeutic Delivery of LXR Agonists Suppresses Melanoma Tumor Growth
We next investigated the therapeutic impact of LXR agonists on melanoma. Orally administering low doses (20 mg/kg) of GW3965 or T0901317 to immunocompetent mice bearing established subcutaneous B16F10 mouse melanoma tumors suppressed tumor growth by 67% and 61%, respectively (Figures 2A and 2B) , whereas administering a higher LXR agonist dose (100 mg/kg) reduced tumor growth by 80% (Figure 2A ). For all subsequent studies, we utilized GW3965, given its lower EC 50 for LXRb (Collins et al., 2002) . Oral administration of GW3965 also robustly suppressed tumor growth by the MeWo (70% inhibition) and SK-Mel-2 (49% inhibition) human melanoma cell lines, as well as the SK-Mel-334.2 primary human melanoma line (73% inhibition) . Encouraged by the robust tumor-suppressive impact of LXR agonists on established small tumors (5-10 mm 3 ) (Figures 2A-2E ), we next found that LXR activation therapy also inhibited the growth of large ($150 mm 3 ) tumors by 50% ( Figure 2F ). Remarkably, GW3965
therapy elicited partial tumor regression and stabilization of tumor growth by the B-Raf wild-type MeWo line beyond 100 days ( Figure 2G ). Importantly, all members of this entire GW-treated cohort remained alive beyond 120 days ( Figure 2H ). Administering GW3965 after tumor establishment also prolonged overall survival times in an immunocompetent model and a primary human graft model (Figures S2B and S2C) . Taken together, these findings are consistent with broad-spectrum efficacy of LXR activation therapy across melanotic and amelanotic melanoma tumors of diverse mutational subtypes: B-Raf and N-Ras wild-type (Figures 2A-2C) , B-Raf mutant ( Figure 2D ), and N-Ras mutant ( Figure 2E ). GW3965 administration substantially reduced the number as well as the size of endothelial vessels present in tumors . This was accompanied by a modest All data are represented as mean ± SEM. Scale bars, 50 mm. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S1 .
decrease (23%) in the number of actively proliferating tumor cells in vivo ( Figure 2L ) without a change in the number of apoptotic cells ( Figure S2G ). These results suggest that, in addition to reducing invasion, LXR activation suppresses melanoma tumor growth primarily through inhibiting tumor angiogenesis with a resulting reduction in in vivo tumor cell proliferation.
LXR Agonism Suppresses Melanoma Metastasis to the Lung and Brain
The strong suppressive effects of LXR agonists on melanoma tumor growth motivated us to examine whether LXR activation could also suppress metastatic colonization by melanoma cells. Remarkably, mice that were orally administered GW3965 or (legend continued on next page) T0901317 exhibited 31-and 23-fold less lung metastatic burden, respectively, from human MeWo cells ( Figures 3A and 3B ). Treatment also suppressed metastatic colonization by the HT-144 line ( Figure 3C ) as well as the SK-Mel-334.2 primary human line (Figure 3D ). Additionally, oral administration of GW3965, a lipophilic molecule, inhibited both brain metastatic colonization and systemic metastasis following intracardiac injection of brainmetastatic melanoma cells derived from the MeWo parental line ( Figures 3E and 3F ). These results reveal robust metastasis suppression by LXR activation therapy across multiple melanoma lines and in multiple distal organ metastatic sites. We next tested the effects of LXR agonism on orthotopic metastasis ( Figure 3G ). Oral administration of GW3965 posttumor resection inhibited lung colonization by disseminated melanoma cells by 17-fold ( Figure 3H ). Remarkably, initiating therapy after incipient metastases had progressed by 8-fold from the baseline at seeding also dramatically suppressed (28-fold) metastatic colonization ( Figure 3I ) and reduced the number of macroscopic nodules observed ( Figure 3J ). Finally, treatment in this preclinical ''adjuvant'' paradigm significantly prolonged survival times following metastatic dissemination ( Figure 3K ).
LXRb Activation Suppresses Melanoma Phenotypes by Transcriptionally Inducing Melanoma Cell ApoE Expression
The inhibitory effects of LXR agonists on cell-extrinsic endothelial recruitment by melanoma cells are consistent with the action of a secreted molecule. Transcriptomic profiling revealed 41 secreted factors to be significantly upregulated in human MeWo melanoma cells in response to GW3965 treatment (Table  S1 ). Interestingly, we identified ApoE, a previously validated transcriptional target of LXRs in macrophages and adipocytes (Laffitte et al., 2001) , as the top upregulated secreted factor. Quantitative real-time PCR (qRT-PCR) validation confirmed the robust LXR-dependent upregulation of ApoE transcript expression in multiple melanoma lines ( Figures S3A-S3C ).
In light of the previously reported metastasis-suppressive function of ApoE in melanoma (Pencheva et al., 2012) , we investigated whether LXRb activation suppresses melanoma progression through transcriptional induction of ApoE. Indeed, GW3965 and T0901317 enhanced the activity of an ApoE promoter/LXR enhancer element reporter (Laffitte et al., 2001 ) in melanoma cells ( Figure 4A ), whereas chromatin immunoprecipitation (ChIP) confirmed endogenous LXRb binding of the ApoE multienhancer element ( Figure 4B ). Importantly, LXR activation raised both intracellular ( Figures 4C-4E ) and secreted ApoE protein levels ( Figures 4F, 4I, S3D ). Notably, antibody-mediated neutralization of ApoE completely prevented the LXRb agonist-mediated suppression of cell invasion and endothelial recruitment ( Figures 4G, 4H , 4J, 4K, S3E, and S3F), revealing the effects of LXR agonism to be mediated by extracellular ApoE. Additionally, ApoE knockdown also blocked the GW3965-mediated suppression of these phenotypes (Figures S3G and S3H) . In agreement with this, melanoma cell depletion of LXRb, but not LXRa, abrogated the ability of GW3965 and T0901317 to upregulate ApoE transcript and protein expression ( Figures 4L, 4M , and S3I-S3K). Collectively, these findings indicate that pharmacologic activation of LXRb suppresses melanoma invasion and endothelial recruitment by transcriptionally activating melanoma cell ApoE expression.
Engagement of Melanoma-Derived and Stromal ApoE by LXRb Activation Therapy
The LXRb-induced suppression of key melanoma phenotypes by extracellular ApoE in vitro suggests that the suppressive effects of LXR agonists in vivo might be further augmented by the activation of LXRs in peripheral tissues, which could serve as additional sources of extracellular ApoE. We found that treatment of mice with either GW3965 or T0901317 significantly elevated ApoE expression in melanoma tumors, metastases ( Figures  S4A-S4E ), systemic adipose, lung, and brain tissues of mice (Figures 5A and 5B), and in circulating white blood cells (Figure 5C ). These results indicate that LXR activation therapy induces ApoE expression in melanoma tumors and in various tissues and organs.
We next investigated the tissue compartments that GW3965 acts on to mediate its tumor-suppressive effects. Interestingly, GW3965 fully inhibited the growth of primary tumors formed by LXRb-depleted cells ( Figures 5D and S4F-S4H ), implicating a role for melanoma-extrinsic (stromal) LXR activation in tumor suppression by GW3965. Genetic inactivation of stromal LXRb, but not LXRa, rendered GW3965 completely ineffective ( Figures  5D, S4M, and S4N ). These findings reveal melanoma-extrinsic/ stromal LXRb to be the primary molecular target and effector of GW3965 in mediating long-term melanoma tumor growth suppression. To test whether melanoma cell LXRb activation contributes to the initial phase of tumor initiation and formation, we pretreated melanoma cells with GW3965, allowing us to isolate melanoma-intrinsic from stromal effects of the LXR agonist treatment. Interestingly, whereas GW3965 pretreatment modestly suppressed primary tumor formation and metastatic tumor initiation in melanoma cells expressing LXRb, the drug failed to inhibit these phenotypes in melanoma cells depleted of LXRb ( Figures S4I-S4L) , consistent with melanoma cell LXRb partly mediating the suppressive effects of GW3965 on the early stage of tumor formation.
We next examined whether ApoE is the downstream effector of in vivo melanoma suppression by LXR agonists. Stromal ApoE was found to be required for GW3965-induced tumor growth suppression as melanoma tumors implanted into ApoE-null mice exhibited no growth reduction in response to GW3965 administration ( Figure 5E ). Accordingly, melanoma cell depletion of ApoE had no effect on GW3965-induced tumor growth suppression . These findings reveal that the tumor suppressive effects of GW3965 are primarily mediated through extracellular ApoE derived from various peripheral stromal tissues and supplied to the tumor via the circulation and/or ApoE production by local stromal cells in the microenvironment. Consistent with this, GW3965 treatment significantly upregulated ApoE expression in macrophages (158%), leukocytes (103%), and endothelial cells (20%) within tumors ( Figures 5F-5I ). Interestingly, metastasis suppression by GW3965 was entirely occluded only in the setting of combined melanoma cell depletion and genetic inactivation of ApoE ( Figure 5J ). We thus conclude that the effects of LXRb on primary tumor growth are elicited primarily through stromal ApoE activation, whereas its effects on metastasis are mediated through ApoE transcriptional induction in both the tumoral and stromal compartments.
Consistent with a role for ApoE in human melanoma progression, we found that patients whose melanomas had metastasized exhibited roughly 3-fold lower ApoE expression in their primary tumors relative to patients whose melanomas had not metastasized ( Figure 5K ). Remarkably, ApoE expression levels robustly stratified patients at high risk from those at low risk for metastatic relapse ( Figure 5L ) and predicted overall patient's survival ( Figure 5M ). Consistent with this, distal melanoma metastases displayed significantly lower ApoE levels relative to primary lesions in two independent TMA melanoma progression sets ( Figure S5A ; Pencheva et al., 2012 Figures 6D-6F ). Collectively, these findings indicate that LXRb activation reduces primary tumor progression, orthotopic and experimental metastasis, and mortality rates in genetically driven melanoma models.
LXRb Activation Suppresses Melanomas Resistant to Dacarbazine and Vemurafenib
In order to test the effect of LXRb-activation therapy on populations that have acquired resistance to approved melanoma therapies, we in vitro derived a B16F10 clone that showed a 7-fold increase in survival when cultured in high-dose dacarbazine (DTIC) ( Figure S6C ) and displayed in vivo resistance relative to its parental line ( Figures 6G and 6H ). Of note, GW3965 administration robustly suppressed tumor growth by this DTIC-resistant subline by more than 70% ( Figures 6H and 6I) . Remarkably, oral delivery of GW3965 also strongly inhibited ($70%) the growth of an independent in vivo selected DTIC-resistant MeWo subline ( Figures 6J-6L ). GW3965 treatment also suppressed the growth of two previously derived independent SK-Mel-239 vemurafenib-resistant clones (C1 and C5), which attained resistance to vemurafenib through distinct mechanisms (Poulikakos et al., 2011) , by 72% ( Figure 6M ) and 39% ( Figure S6D ), respectively, and prolonged the survival of mice bearing vemurafenib-resistant melanoma burden ( Figure 6N ). Additionally, GW3965 reduced by 50% the growth of tumors generated by a B-Raf-mutant/vemurafenibresistant primary mouse subline that we derived through in vivo selection ( Figures 6O and S6E) . These results reveal that LXRb agonism is effective in suppressing multiple melanoma sublines resistant to the widely used B-Raf kinase inhibitor vemurafenib and the sole FDA-approved cytotoxic chemotherapeutic in melanoma, dacarbazine. A) Luciferase activity driven off an ApoE promoter construct fused to ME.1 or ME.2 enhancers and introduced into melanoma cells treated with DMSO, GW3965, or T0901317 at 1 mM for 24 hr. n R 4. (B) ChIP of genomic ME.2 DNA in MeWo cells using an endogenous LXRb antibody. The ChIP product was analyzed by qRT-PCR using primers spanning a ME.2 region containing the LXR binding element (LXRE-pos). Data are expressed as fold enrichment relative to a genomic region lacking the LXR element (LXRE-neg). n R 3. (C-E) ApoE protein levels in MeWo (C), , and SK-Mel-334.2 (E) cells treated with DMSO, GW3965, or T0901317 at 1 mM for 72 hr. ApoE expression was normalized to tubulin. n R 3. (F) Extracellular ApoE levels quantified by ELISA in conditioned media from MeWo cells treated with DMSO, GW3965, or T0901317 at 1 mM for 72 hr. n R 3. (G and H) Matrigel invasion and endothelial recruitment by MeWo cells, treated with DMSO, GW3965, or T0901317 at 1 mM for 72 hr, in response to an ApoE neutralization antibody (1D7) or IgG added at 40 mg/ml. n R 6. (I) Extracellular ApoE levels in conditioned media from SK-Mel-334.2 primary human melanoma cells treated with DMSO or GW3965 at 1 mM for 72 hr. n = 4. (J and K) 5 3 10 4 SK-Mel-334.2 cells, pretreated with DMSO or GW3965 at 1 mM for 72 hr, were subjected to the matrigel invasion (J) and endothelial recruitment (K) assays in the presence of 1D7 or IgG antibodies. n R 7.
(L) Luciferase-based activity of an ApoE promoter + ME.1/ME.2 construct transfected into MeWo cells expressing a control shRNA or shRNAs targeting LXRa or LXRb in response to DMSO or GW3965 (1 mM) treatment for 24 hr. n R 3. (M) Extracellular ApoE protein levels in MeWo cells transduced with a control shRNA or shRNAs targeting LXRa or LXRb and treated with GW3965 or T0901317 (1 mM) for 72 hr. n R 3. All data are represented as mean ± SEM. Scale bars, 50 mm. See also Table S1 and Figure S3 .
LXRb Therapy Cooperates with Mainstay Melanoma Therapeutics in Suppressing Melanoma Progression
We next investigated combination regimens. Namely, whereas either GW3965 or DTIC treatment alone inhibited B16F10 tumor growth by 65% and 70%, respectively, combined GW3965 and DTIC therapy led to a greater than 90% suppression of tumor growth ( Figure 7A ). We further found that combined GW3965 and vemurafenib treatment suppressed tumor progression by the B-Raf mutant A375 line by 82%, which significantly exceeded the inhibition seen with each drug alone: 44% for GW3965 and 65% for vemurafenib (Figures 7B and 7C) . Additionally, alternating vemurafenib and LXR agonist therapy was more effective on tumor growth suppression ($74%) than single-agent GW3965 (62%) or vemurafenib (57%) treatment ( Figure 7D ) and on survival outcomes ( Figure 7E ). Such cooperativity was also evident in metastatic colonization assays involving multiple cell lines ( Figures 7F  and 7G ). Finally, we investigated cooperativity between LXRb activation and immunotherapy. Although anti-CTLA-4 antibody (Ab) monotherapy inhibited melanoma growth by 20% (van Elsas et al., 1999), GW3965 therapy inhibited growth by over 60%. Remarkably, combining these agents elicited a greater than 80% inhibition in tumor growth and further improved survival outcomes relative to each drug alone, revealing additivity between the effects of GW3965 and anti-CTLA-4 Ab therapy (Figures 7H and 7I) .
In summary, we find that LXR agonist treatment suppressed melanoma progression to a degree comparable to and/or greater than that of the current FDA-approved mainstay melanoma therapeutics. Importantly, combining GW3965 treatment with either DTIC, vemurafenib, or the anti-CTLA-4 antibody led to significantly greater melanoma suppression than each treatment alone. Our findings from combined pharmacologic, molecular, and genetic studies in diverse preclinical models of melanoma establish LXRb targeting as a promising therapeutic approach that robustly suppresses melanoma progression through the transcriptional induction of ApoE-a key suppressor of melanoma invasion and metastatic angiogenesis (Pencheva et al., 2012;  Figure 7J ).
DISCUSSION
Metastatic melanoma remains a formidable clinical challenge (Bhatia et al., 2009 ). Novel targeted agents have extended survival times in subsets of patients by an average of 4-10 months (van Elsas et al., 1999; Hodi et al., 2010; Yang et al., 2010; Chapman et al., 2011; Sosman et al., 2012) , with some patients exhibiting durable responses to anti-CTLA-4 therapy. Despite this, the sole path to cure for metastatic melanoma still remains prevention of metastatic relapse, for which there currently exists no effective therapeutic regimen .
Remarkably, LXRb agonism suppressed the in vivo progression of diverse melanoma subtypes, harboring activating mutations in the oncogenes B-Raf or N-Ras, inactivating mutations in the tumor suppressors Pten or CDKN2A, or wild-type for B-Raf and N-Ras (Hodis et al., 2012) . Our results also reveal cooperativity between this approach and the frontline regimens dacarbazine, vemurafenib, and anti-CTLA-4 Ab. Combination regimens incorporating LXR activation further improved melanoma progression outcomes relative to treatment with each therapeutic alone. Additionally, oral delivery of LXR agonists suppressed the progression of established lung metastases and reduced brain metastatic colonization-an intractable clinical condition that lacks an effective FDA-approved therapeutic. We further find that LXRb agonism strongly inhibited the in vivo growth of melanoma lines resistant to dacarbazine and vemurafenib. Taken together, these findings compellingly support LXRb activation as a broad-spectrum therapy in melanoma and have important clinical implications for patients whose melanomas do not respond to approved agents, metastasize to the brain, and/or develop resistance to dacarbazine or vemurafenib.
The robust melanoma-suppressive effects of LXR agonists occurred in the absence of any noted adverse effects such as weight loss ( Figure S2A ) or symptomatic health deterioration in response to high-dose GW3965 administration in long-term mouse experiments. LXR agonists were originally developed and conceived of as lifelong therapies for the chronic management of dyslipidemia. The clinical application of GW3965 and its related congener, however, was stalled when these two compounds were found to lack efficacy in reducing cholesterol levels in primates (Groot et al., 2005) . Although there is some continued interest in clinically developing this class for cardiovascular indications, our findings suggest promise for LXR agonists in the management of melanoma. Nuclear hormone receptor targeting has proved extremely effective in managing sex-hormone-driven malignancies such as breast and prostate cancers. However, in contrast to breast and prostate cancers where the ''antagonism'' of estrogen and androgen receptors, respectively, suppresses cancer progression by inhibiting the transcription of genes driving cancer proliferation (Deblois and Giguè re, 2013; Tran et al., 2009 ), we find that pharmacologic ''agonism'' of LXRb inhibits the growth and metastasis of melanoma by uniquely transcriptionally activating the expression of a metastasis suppressor gene (ApoE) that acts within the tumor microenvironment. We previously found that this secreted factor suppressed melanoma invasion by binding the LRP1 receptor on melanoma cells, whereas it suppressed endothelial recruitment and migration by engaging endothelial LRP8 receptors. The coordinate inhibition of these cell-autonomous/non-cell-autonomous phenotypes by ApoE accounts for its remarkable activity in vivo (Pencheva et al., 2012) .
LXRa and LXRb, which were cloned by multiple groups (Willy et al., 1995; Apfel et al., 1994; Song et al., 1994) , belong to a family of nuclear hormone receptors that are endogenously activated by various oxysterols (Janowski et al., 1996) . Recently, 27-hydroxycholesterol, an oxysterol that acts as a partial LXR agonist, was shown to promote metastatic dissemination by murine breast cancer cells (Nelson et al., 2013) . In contrast to this, we herein report that LXR activation suppresses human and mouse melanoma metastasis. The different roles of LXR agonism in breast versus melanoma metastasis could be due to cancer type-specific differences or 27-hydroxycholesterol's partial agonism of LXR signaling.
Although nuclear hormone receptors such as ER, AR, and LXR transcriptionally activate multiple genes, our genetic and molecular studies reveal the effects of GW3965 on melanoma progression to be primarily mediated by a single LXRb target gene: ApoE. While we cannot exclude that LXRb activation induces additional targets that may contribute to melanoma suppression along with ApoE, our findings of complete LXR agonist inactivity upon ApoE genetic inactivation suggest that ApoE is the primary determinant of melanoma suppression in response to LXR agonism.
We uncover an important role for stromal ApoE in mediating the effects of LXR agonists on melanoma progression. Interestingly, whereas tumor growth inhibition was primarily driven by ApoE induction in stromal cells, metastasis suppression by GW3965 was elicited through the activation of both stromal and melanoma-derived ApoE (Figures 5E and 5J) . We speculate that relative tissue-specific differences in microenvironmental ApoE expression (lower in lung relative to skin, Figures S5B  and S5C ) confer the differential impact of melanoma-derived ApoE in suppressing tumor growth versus metastasis. The reduced expression of ApoE in the lung relative to the skin may provide melanoma cells a hospitable niche and, as such, may contribute to the clinically evident organotropism of melanoma cells for the lung.
Our findings reveal that ApoE activation therapy suppresses metastatic initiation. We believe that this is in part due to ApoE's demonstrated capacity to reduce endothelial cell recruitment by melanoma cells in vivo. How might suppressed endothelial recruitment impact metastatic initiation? We had previously shown that highly metastatic human breast cancer cells (Png et al., 2012) and melanoma cells (Pencheva et al., 2012) display enhanced ability to promote endothelial recruitment in vitro and in vivo. Although angiogenesis is thought to promote tumor growth primarily through its enhancement of blood perfusion, we had previously found that metastatic endothelial recruitment (MER) can trigger the initiation of metastases (Png et al., 2012) . The current work further supports a role for MER in metastatic progression by revealing that ApoE activation therapy, which diminishes endothelial content within melanoma tumors in vivo, robustly suppresses metastatic initiation by melanoma cells.
Advanced melanomas display tremendous molecular versatility, allowing them to develop resistance to targeted therapies (Nazarian et al., 2010; Shi et al., 2012; Prahallad et al., 2012) . In contrast, nontransformed stromal tissues are less prone to All data are represented as mean ± SEM. Scale bar, 5 mm except for (B) (2 mm). See also Figure S6 .
network plasticity and the acquisition of resistance. Our findings of chronic elevation of ApoE in nontransformed stromal tissues in response to LXR activation suggest that patients treated with LXR therapy may be less vulnerable to the emergence of resistance. However, a solution to eventual resistance outcomes, such as LXRb mutational and/or expression alterations, would be the development of next-generation LXRb agonists that could bind and activate a potentially mutated/deregulated receptor with greater potency (O'Hare et al., 2005; Tran et al., 2009 ). An alternative path would be to enhance ApoE posttranscriptionally through locked nucleic acid (LNA)-based inhibition of melanoma metastasis-promoting microRNAs miR-199a-3p, miR-199a-5p, and miR-1908 that convergently target ApoE (Pencheva et al., 2012) , which might overcome potential resistance to ApoE transcriptional activation therapy. Additionally, the feasibility of therapeutically inducing ApoE using both pharmacologic LXR agonism and LNA-based miRNA silencing mechanisms suggests potential for therapeutic cooperativity upon combined transcriptional/posttranscriptional ApoE modulation. ) mice were obtained from the Jackson Laboratory. For experiments testing the effect of LXR agonists on tumor growth, mice were assigned to a control chow or a chow supplemented with GW3965 (Sigma-Aldrich, AdooQ Bioscience) or T0901317 (Tocris Bioscience) at 20, 75, or 100 mg/kg/day, as indicated. For therapeutic metastasis formation studies, mice were fed a control diet or an LXR agonist-supplemented diet starting 10 days prior to cancer cell injection, unless otherwise specified. 4-HT (70% Z-isomer, Sigma-Aldrich) at 25 mg/kg, administered in peanut oil on 3 consecutive days, and assigned to a control diet or a GW3965 diet (100 mg/kg). For combination drug regimens, mice were fed a GW3965-supplemented diet and cotreated with DTIC (Sigma-Aldrich), 50 mg/kg by i.p. injection; vemurafenib (Genentech), diet-supplemented at 50 mg/kg; and immunoglobulin (Ig) G or anti-CTLA-4 Ab (BioXcell), 100 mg/mouse followed by two consecutive 50 mg/mouse doses every 3 days by i. 
ApoE Expression Analysis in Melanoma Clinical Samples
Clinical samples were procured, processed, and analyzed in agreement with IRB guidelines. Primary melanoma skin lesions were previously resected from patients at the MSKCC, formalin-fixed, paraffin-embedded, and sectioned at 5 mm intervals. ApoE protein expression was assessed by double-blinded immunohistochemical analysis using the D6E10 anti-ApoE antibody (ab1906, Abcam). See Extended Experimental Procedures.
Data Analysis
Significance of non-Gaussian bioluminescence measurements was determined using the Mann-Whitney t test. The Mantel-Cox log-rank test was used for statistical comparisons in survival analyses. The KolmogorovSmirnov test was employed in comparing ApoE staining intensity cumulative distributions. All other statistical comparisons were carried out using Student's t tests. Throughout all figures, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. Significance was concluded at p < 0.05.
ACCESSION NUMBERS
Microarray gene expression data from the MeWo human melanoma line in response to GW3965 treatment are deposited at Gene Expression Omnibus (GEO) under the accession number GSE48782. 
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